Accro Bioscience's AC-101 Tablets Join NMPA's Rare Disease Development Initiative

On September 14, 2026, Accro Bioscience made a significant announcement regarding its AC-101 tablets, which have just been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program, also known as the "Caring Plan-Extension." This initiative is orchestrated by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) and aims to foster development for treatments targeting rare diseases, specifically citing Blau syndrome as the intended application for AC-101. The public notice period for this announcement concluded on September 11, 2026.

Earlier this year, in June 2026, the U.S. Food and Drug Administration (FDA) had already granted AC-101 the designation of Rare Pediatric Disease (RPD) for its use in treating Blau syndrome. This growing recognition by regulatory agencies reflects a rising confidence in the potential of AC-101 to address currently unmet medical needs.

Understanding AC-101

AC-101 is a groundbreaking selective RIPK2 inhibitor developed through Accro Bioscience’s proprietary drug discovery platform. The drug targets regulatory cell death and inflammation pathways, placing it at the forefront of therapeutic options for conditions characterized by similar mechanisms, such as moderate-to-severe ulcerative colitis (UC). The receptor interacting protein kinase 2 (RIPK2) plays a pivotal role in mediating the NOD signaling pathway, with disruptions linked to various inflammatory and autoimmune disorders, including inflammatory bowel disease (IBD).

The clinical journey of AC-101 has demonstrated promising safety and pharmacokinetic/pharmacodynamic (PK/PD) profiles through successful completion of Phase I trials in healthy individuals across Australia and China. Additionally, a Phase Ib/IIa proof-of-concept study involving Chinese patients with moderate-to-severe UC has finished. The findings regarding efficacy and safety from this clinical trial are set to be shared at UEG Week 2026, creating anticipation among medical professionals and stakeholders.

Insights into Blau Syndrome

Blau syndrome itself is a rare autoinflammatory condition that arises from pathogenic variations in the NOD2 gene. It typically manifests early in childhood and can affect multiple systems, notably the skin, joints, and eyes. The classic symptoms associated with this syndrome include a triad of granulomatous dermatitis, arthritis, and uveitis. If left untreated, joint involvement can lead to deformities and impair functional capabilities over time, while ocular issues from uveitis may result in severe visual impairments or blindness if not managed swiftly.

A Leader in Biotechnology

Accro Bioscience Inc., now gaining traction within the clinical-stage biotechnology sector, is devoted to the discovery, development, and commercialization of innovative medications targeting inflammatory and autoimmune illnesses. Their current pipeline boasts a range of first- and best-in-class compounds, showcasing the potential to introduce transformative therapies that may reshape treatment paradigms.

For more details on their research and available products, check out Accro Bioscience's official website. The future looks promising for AC-101 as it embarks on this critical journey towards improved healthcare solutions for patients suffering from Blau syndrome and beyond.